Renescience A/S — Regnskab

CVR 31846803

Seneste regnskabsperiode

  • 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • 21000 • -5425000 • -6163000 • -503937000 • 81310000 • 73470000 • 1000

Regnskabshistorik

  • 2024 • 2024-01-01 • 2024-12-31 • entity • DKK • 10836000 • -15360000 • -17785000 • -23904000 • 14580000 • 7407000 • 1000
  • 2023 • 2023-01-01 • 2023-12-31 • entity • DKK • 10419000 • -13537000 • -36452000 • -194649000 • 32791000 • -11689000 • 0
  • 2022 • 2022-01-01 • 2022-12-31 • entity • DKK • 10831000 • -10887000 • -12708000 • -13301000 • 217391000 • 182960000 • 0
  • 2021 • 2021-01-01 • 2021-12-31 • entity • DKK • 7970000 • -11415000 • -12015000 • -8322000 • 35921000 • 22754000
  • 2020 • 2020-01-01 • 2020-12-31 • entity • DKK • 1692000 • -16589000 • -17307000 • -13492000 • 34789000 • 31076000
  • 2019 • 2019-01-01 • 2019-12-31 • entity • DKK • -23169000 • -23221000 • -18126000 • 50085000 • 44568000
  • 2018 • 2018-01-01 • 2018-12-31 • entity • DKK • -24267000 • -24267000 • -19092000 • 71186000 • 62694000

Højdepunkter fra årsrapporten

  • primary activities • The Company's objects are to conduct business within the environmental and energy sector and related activities. On 16 December 2024, Renescience A/S entered into a Share Purchase Agreement for the sale of its subsidiaries, Ørsted Renescience Northwich Ltd. and Ørsted Renescience Northwich O&M Ltd. The transaction was completed on 31 October 2025. A key term of the agreement required the subsidiaries to be sold on a debt-free basis. To satisfy this condition, Renescience A/S made an additional capital contribution to Ørsted Renescience Northwich Ltd. prior to closing. This capital injection was impaired to reflect the impact of the transaction in the Annual Report. Following the transaction, the Company has very limited activity. • entity
  • primary activities • The Company's objects are to conduct business within the environmental and energy sector and related activities. On 16 December 2024, Renescience A/S entered into a Share Purchase Agreement for the sale of its subsidiaries, Ørsted Renescience Northwich Ltd. and Ørsted Renescience Northwich O&M Ltd. The transaction was completed on 31 October 2025. A key term of the agreement required the subsidiaries to be sold on a debt-free basis. To satisfy this condition, Renescience A/S made an additional capital contribution to Ørsted Renescience Northwich Ltd. prior to closing. This capital injection was impaired to reflect the impact of the transaction in the Annual Report. Following the transaction, the Company has very limited activity. • entity
  • contingent liabilities • The group's Danish companies are jointly and severally liable for tax on group jointly taxes income, etc. Reference is made to the annual report for Ørsted A/S, the administration company in relation to joint taxation. The group's Danish companies are also jointly and severally liable for Danish withholding taxes on dividends, royalties and interests within the group of jointly taxed entities. Any subsequent corrections to income and withholding taxes may result in an increase in the entities' liability. The group's danish entities are jointly and severally liable for joint VAT registration. • entity